Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 1

Deferasirox alımına sekonder gelişen tip-I hipersensitivite reaksiyonu

Type-I hypersensitivity reaction secondary to deferasirox intake

Pages
42–44
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here in we showed when the defasirox was used first time even it caused some allergic reactions, however during the time period it can be used again due to the possibility of development of immune tolerance.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Deferasirox is a new generation tridentate iron chelator.
📊
Key Findings & Data:The skin prick, intradermal and patch tests and oral deferasirox provocation test were performed after 1 year, and the former reaction did not appear.
💡
Conclusion & Impact:Here in we showed when the defasirox was used first time even it caused some allergic reactions, however during the time period it can be used again due to the possibility of development of immune tolerance.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Deferasirox is a new generation tridentate iron chelator. We report a ten-year old ß-thalassaemic boy, who had type-I hypersensitivity reaction due to deferasirox intake. At the seventh day of deferasirox treatment, he admitted to our clinic with the complaints of pruritic skin rash which began from the neck that spreaded throughout the body. After the termination of deferasirox treatment, the rash didn't recur. When deferasirox was restarted, similar skin rashes reappeared immediately. The skin prick, intradermal and patch tests and oral deferasirox provocation test were performed after 1 year, and the former reaction did not appear. Here in we showed when the defasirox was used first time even it caused some allergic reactions, however during the time period it can be used again due to the possibility of development of immune tolerance.

Özet

Deferasirox yeni jenerasyon tridente bir demir şelatörüdür. Burada deferasirox alımına bağlı tip-I hipersensivite reaksiyonu gelişen on yaşında ß-thalassemili bir erkek çocuk sunuyoruz. Hasta, deferasirox tedavisinin yedinci gününde boyundan başlayarak tüm vücuda yayılan kaşıntılı deri döküntüleri şikayetiyle başvurdu. Deferasirox tedavisi kesildikten sonra döküntüler tekrarlamadı. Deferasirox tekrar başlandığında deri döküntüleri hızla tekrar ortaya çıktı. Deri prick ve intradermal testleri ve oral provakasyon testi 1 yıl sonra yapıldı ve eski döküntü reaksiyonu gözlenmedi. Bu olgu ile deferasirox ilk kullanıldığında allerjik reaksiyona neden olsa da zaman içinde olası immun tolerans gelişimi nedeniyle tekrar kullanılabileceğini gösterdik.

🔖

Cite This Article

IŞIK, P., YARALI, H. N., BAY, A., ÖZMEN, S., TUNÇ, B. (2010). Deferasirox alımına sekonder gelişen tip-I hipersensitivite reaksiyonu. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 1, 42–44. https://ajindex.com/articles/322930

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Delea TE, Sofrygin O, Thomas SK. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in infusion-dependent thalassemia patient. Pharmaeconomics 25: 329-342, 2007
  2. Vichinsky E. Clinical application of deferasirox: pratical patient management. Am J Hematol 83: 398-402, 2008
  3. Porter J, Galanello R, Saglio G. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670). Eur J Haematol 80: 168-176, 2008
  4. Peng CT, Chang JS, Wu KH. Mechanisms of and obstacles to iron cardiomyopathy in thalassemia. Front Biosci 1: 5975-5987, 2008
  5. Nick H-P, Acklin P, Lattmann R. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem 10: 1065-1076, 2003
  6. Walter PB, Macklin EA, Porter J. inflammation and oxidant-stress in beta thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine. Haematologica 93: 817-825, 2008
  7. Lindsey WT, Olin BR. Deferasirox for transfusion-relat- ed iron overload. Clin Ther 29: 2154-2166, 2007.